Infertility in men with inflammatory bowel disease

Takeshi Shin, Hiroshi Okada

Abstract

Infamatory bowel disease (IBD) predominantly affects young adults. Fertility-related issues are therefore important in the management of patients with IBD. However, relatively modest attention has been paid to reproductive issues faced by men with IBD. To investigate the effects of IBD and its treatment on male fertility, we reviewed the current literature using a systematic search for published studies. A PubMed search were performed using the main search terms “IBD AND male infertility”, “Crohn’s disease AND male infertility”, “ulcerative colitis AND male infertility”. References in review articles were used if relevant. We noted that active inflammation, poor nutrition, alcohol use, smoking, medications, and surgery may cause infertility in men with IBD. In surgery such as proctocolectomy with ileal pouch-anal anastomosis, rectal incision seems to be associated with sexual dysfunction. Of the medications used for IBD, sulfasalazine reversibly reduces male fertility. No other medications appear to affect male fertility significantly, although small studies suggested some adverse effects. There are limited data on the effects of paternal exposure to IBD medications on pregnancy outcomes, but no significant increase in fetal risk has been noted except for thiopurines. Patients should be informed of the possible effects of paternal drug exposure. This review provides information on fertility-related issues in men with IBD and discusses treatment options.

Key words: Crohn’s disease; Infertility; Inflammatory bowel disease; Male; Ulcerative colitis
appropriately informed of possible effects of paternal drug exposure.

Shin T, Okada H. Infertility in men with inflammatory bowel disease. *World J Gastrointest Pharmacol Ther* 2016; 7(3): 361-369 Available from: URL: http://www.wjgnet.com/2150-5349/full/v7/i3/361.htm DOI: http://dx.doi.org/10.4292/wjgpt.v7.i3.361

**INTRODUCTION**

Inflammatory bowel disease (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) is a chronic intestinal disorder usually diagnosed in early adulthood. The incidence of IBD has been found to be the highest between the second and fourth decade of life[13], and fertility-related issues are therefore important clinical considerations.

Infertility is defined as a disease of the reproductive system characterized by failure to achieve a clinical pregnancy after ≥ 12 mo of regular unprotected sexual intercourse[2]. Much attention has been focused on issues related to fertility in women with IBD, but relatively little attention has been paid to the reproductive issues faced by men with IBD. Male infertility is thought to be more prevalent in IBD patients than in the general population[12]. From a case control study, Moody *et al.*[9] showed that the number of children born to men with CD is significantly lower in comparison to men with UC and the general population, but found no difference in the number of children between men with UC and the general population. Notably, the fecundability of the three groups did not differ significantly[9], and the frequency of sexual intercourse was not significantly different between the patients with IBD and the matched controls[9]. Heetun *et al.*[11] suggested that the smaller family size might be due to a fear of passing on the disease to offspring or a decision to limit family size rather than a physical effect of the disease. A recent systematic review of non-surgically treated men with CD revealed a 18%-50% reduction in fertility with no difference in reproductive capacity[8].

Even if overall IBD itself does not seem to affect fertility in men, medications used to treat the disease, surgery, and malnutrition resulting from IBD may cause male infertility, including sexual dysfunction. Table 1 shows the possible causes of infertility in men with IBD. This article summarizes sexual and reproductive issues associated with male IBD patients.

| Causes of infertility in men with IBD | Ref. |
|--------------------------------------|------|
| Surgery [17,19-25]                   |      |
| Medications [4,5,7,15,16,28-32,42,43] |      |
| Active disease [15,16,76]            |      |
| Poor nutrition [15,77]               |      |
| Alcohol use [15,81-83]               |      |
| Tobacco use [15,83,86,87]            |      |
| Psychological factor [7,88,89]       |      |

**Surgery causing male infertility**

It is estimated that approximately 25%-35% of UC patients will ultimately require surgery for either a complication of the disease or inadequate control of symptoms, and 70%-90% of CD patients will need a surgical intervention at some point in the course of their disease[9-11]. Surgery is required in cases of failure of medical management, risk of malignancy, intestinal obstruction and toxic megacolon. Especially in patients with CD, complications such as perianal abscesses, fistulas, and stenosis can occur during the course of the disease, and surgery is often indicated in these cases[12,13]. Surgical treatment of perianal fistulas ranges from minimal surgery like seton and fistulotomy to definitive surgery with closure of the fistula tract or proctectomy and fecal diversion[13]. Currently, the most frequently performed surgical procedure for UC is restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA), while intestinal resection is the most commonly performed surgical procedure for CD[14].

Proctocolectomy with IPAA seems to be associated with sexual dysfunction in men[15,16]. The sexual disturbances after proctocolectomy are usually due to damage to parasympathetic and sympathetic nerves during surgery, but sometimes due to anatomical alterations, fibrosis, or psychological factors[17].

Sexual dysfunction is one of the etiologies of male infertility, and it includes erectile dysfunction and ejaculatory dysfunction such as retrograde ejaculation and anejaculation (no ejaculation). A meta-analysis found that the pooled incidence of sexual dysfunction from 21 studies comprising 5112 patients was 3.6%[18], but this meta-analysis included both men and women. When focusing on only men, Berndtsson *et al.*[19] found that 12% of male patients with UC had ejaculatory dysfunction after IPAA. In a retrospective study, Hueting *et al.*[20] showed the incidence of erectile dysfunction or retrograde ejaculation in such patients to be 25.7%. A study of 122 men who underwent IPAA found that the prevalence of retrograde ejaculation increased from 1.6% preoperatively to 8.2% postoperatively, but the prevalence of erectile dysfunction was similar before and after IPAA[21]. On the other hand, a large study by Farouk *et al.*[22] found sexual dysfunction in 1% of male patients (n = 762) at 1 year after IPAA, and in 2% (n = 215) at 12 years after IPAA. Table 2 shows an overview of past studies of sexual function after proctocolectomy in men[17,19-25]. Regarding the treatment of sexual dysfunction due to rectal excision, there has been one randomized placebo-controlled trial for sildenafil for erectile dysfunction[26]. This study showed a successful
response in 79% of patients in the sildenafil-treated group. Given these data, Feagins et al. suggested that they could reassure male patients that the occurrence of postoperative sexual dysfunction after IPAA for IBD is low and, when it does occur, it can be successfully treated with sildenafil in most cases. However, sperm banking should be offered before surgery considering that some patients with erectile dysfunction after IPAA fail to respond to medications and some patients may develop ejaculatory dysfunction after surgery, although they are few in number.

There are other surgical options for IBD apart from IPAA, but the data on postoperative fertility (or sexual function) remain limited. One report by Hultén suggested that ileo-rectal anastomosis has the advantage of avoiding rectal dissection and the associated risks of sexual disturbance, but increases the risk of cancer in the rectal stump. Good results in colectomy with ileo-rectal anastomosis require appropriate patient selection, good rectal distensibility criteria, and accurate endoscopic and histological surveillance for prompt treatment of any recurrence of pouchitis or onset of premalignant changes.

### MEDICATIONS CAUSING MALE INFERTILITY

Table 3 summarizes the effect of IBD medications on male fertility and the partner’s pregnancy outcomes. It also notes recommendations for discontinuation of medications before attempting to conceive.

**Sulfasalazine and 5-aminosalicylates**

Sulfasalazine and 5-aminosalicylates (5-ASAs) have been used for the initial treatment of IBD and for long-term maintenance of disease remission. These drugs have anti-inflammatory activity.

Levi et al. first reported 4 cases of male infertility associated with sulfasalazine in 1979. In all 4 cases, discontinuation of sulfasalazine led to successful conception. Subsequent studies showed that this medication causes reversible non-dose-dependent quantitative and qualitative abnormalities of sperm in > 80% of men. Birnie et al. examined 21 men with CD who received sulfasalazine and found that 18 of them had abnormal semen analysis results and 15 had oligozoospermia. Another study by Moody et al. showed that 25% of men with UC who had no children, compared with 15% of men in the general population. They also found that 60% of male IBD patients who had no children were taking sulfasalazine. Sulfasalazine is a molecule that has two components: 5-ASA and sulfapyridine. The sulfapyridine metabolite is thought to be responsible for adverse effects on sperm, causing impaired sperm maturation or oxidative stress production. However, Wu et al. found no correlation between reactive oxygen species production and sperm density, sperm motility, or hamster oocyte penetration capacity. The adverse effects of sulfasalazine on sperm have been shown to be fully reversible after discontinuation of sulfasalazine.

Restoration of semen quality and fertility has also been shown after switching to a different 5-ASA compound without the sulfapyridine component, such as mesalazine (also called mesalamine). Zelissen et al. evaluated semen quality in 11 patients with IBD during sulfasalazine treatment and 4 mo after replacing sulfasalazine with an oral slow-release preparation of 5-ASA, and observed significant improvements in sperm count, morphology, and motility during 5-ASA treatment in comparison with sulfasalazine treatment. Notably, 3 pregnancies occurred during the study period.

On the other hand, there is a case report of mesalamine-induced oligozoospermia in a young man with UC. In that case, semen analysis results returned to near normal and pregnancy occurred after mesalamine treatment was stopped, but the patient’s semen parameters worsened after resuming mesalamine. Moreover, we have reported a retrospective study of the negative influence of mesalazine on fertility in men with IBD. In this study, 7 of 1225 male subfertile patients had received mesalazine. In 6 of them, mesalazine was discontinued and sperm motility and total mobile sperm count were significantly improved. After discontinuation of mesalazine, 4 of the 6 patients achieved pregnancy with their partners.

### Table 2: Studies of sexual function after proctocolectomy in men

| Ref.          | Year | No. of patients | Disease | Time since surgery | Sexual dysfunction after surgery |
|--------------|------|-----------------|---------|--------------------|---------------------------------|
| Michelessi et al. | 1993 | 26              | UC      | 1.5 yr (median)    | 0% (ED) 19% (EjD)               |
| Damgaard et al.  | 1995 | 26              | UC      | 2.8 yr (median)    | 3.80% (ED) 3.80% (EjD)          |
| Faruk et al.    | 1998 | 215             | UC      | 1 yr               | 1% (EjD)                        |
|                | 2000 | 762             | UC      | 12 yr              | 2% (EjD)                        |
|                | 2000 | 40              | Benign disease | 2.8 yr (median)    | 10% (ED) 12.50% (EjD)           |
| Slors et al.   | 2001 | 156             | CD, UC  | 6.2 yr (median)    | 14% (ED) 0% (EjD)               |
| Lindsey et al. | 2003 | 25              | UC      | 1 yr               | 0% (EjD)                        |
| Berndtsson et al. | 2004 | 36              | CD, UC  | 3.5 yr (median)    | 25.70% (ED)                     |
| Hueting et al. | 2004 | 122             | CD, UC, others | 3.6 yr (median)    | 12% (ED) 8.20% (EjD)            |

CD: Crohn’s disease; ED: Erectile dysfunction; EjD: Ejaculatory dysfunction; UC: Ulcerative colitis.
Table 3  Effects of medications used for inflammatory bowel disease on male fertility

| Medication          | Infertility | Pregnancy complications | Recommendations                  |
|--------------------|-------------|-------------------------|----------------------------------|
| Sulfasalazine      | Reversible  | One study               | Switch to a different 5-ASA      |
| Mesalazine         | One study   | None reported            | Discontinue only in stable disease|
| Corticosteroids    | No          | None reported            | Only use short periods           |
| Thiopurines        | No          | Controversial            | No recommendation                |
| Methotrexate       | Unclear     | None reported            | Discontinue in the case of erectile dysfunction |
| Ciclosporine       | No          | None reported            | No recommendation                |
| Infliximab         | Unclear     | None reported            | No recommendation                |

5-ASA: 5-Aminosalicylate.

However, mesalazine should be discontinued in only patients with stable disease, and it is possible that low IBD activity itself might have contributed to the improved semen analysis results in the patients who discontinued mesalazine.

With respect to pregnancy complications, Moody et al[45] suggested an increased risk of congenital malformations in children born to men on sulfasalazine, but a meta-analysis examining the risk of adverse pregnancy outcomes in women with IBD after exposure to 5-ASAs including sulfasalazine showed no significant increase in congenital abnormalities, stillbirths, spontaneous abortions, preterm deliveries, or low birth weight[44].

From the evidence accumulated to date, discontinuation of sulfasalazine is recommended for prospective fathers, but not discontinuation of 5-ASA compounds lacking the sulfapyridine moiety.

Corticosteroids

Corticosteroids are potent anti-inflammatory agents used for moderate to severe relapses of both CD and UC, but they have no role in maintenance therapy. Corticosteroids inhibit several inflammatory pathways by suppression of interleukin transcription; induction of I-kappa B, which stabilizes the nuclear factor kappa B complex; suppression of arachidonic acid metabolism; and stimulation of apoptosis of lymphocytes within the lamina propria of the gut[45].

Limited data are available on the effects of corticosteroids therapy on fertility for men with IBD. Lerman et al[46] found a reversible reduction in fertility in rats exposed to corticosteroids in spite of no changes in sperm count and motility. In a study of 5 endurance-trained men, Roberts et al[47] showed that an increase in endogenous steroids might be correlated with a subsequent decrease in sperm concentration 74 d later. In contrast, in a study of 70 men with CD and a group of age-matched controls, Burnell et al[48] found no correlation between male infertility and steroid use. In a study of IBD patients undergoing azathioprine (AZA) treatment, the additional administration of corticosteroids had no negative influence on seminogram findings[49]. Definite conclusions regarding the effects of corticosteroids on male fertility cannot be drawn at present because of insufficient data.

Thiopurines

AZA and its active metabolite 6-mercaptopurine (6-MP) are widely used as adjunctive therapy in IBD and as corticosteroid-sparing therapies although they are unapproved therapies for IBD[47].

In a study of 18 men with IBD who received AZA, no worsening of semen analysis results was found, and 6 of the men fathered children during the study period[49]. In a survey of 164 male renal transplant recipients, Xu et al[50] concluded that long-term treatment with cyclosporine, AZA, and corticosteroid had no obvious effect on fertility.

A study of male mice exposed to 6-MP showed no reduction in sperm quantity or quality, but a significantly increased incidence of abortion was noted. The authors suggested that this indicated occult sperm damage[51]. In a study of male patients with IBD who were treated with 6-MP, Rajapakse et al[52] revealed that the incidence of pregnancy-related complications was significantly increased when the father had used 6-MP within 3 mo of conception. Another study showed that paternal use of AZA or 6-MP before conception was associated with an increased, but not statistically significant, risk of congenital abnormalities[16,53]. Conversely, Francella et al[54] found no significant difference in pregnancy outcomes for both men and women taking 6-MP as compared with controls. Teruel et al[55] evaluated the outcomes of pregnancies in which the father was exposed to thiopurines at the time of conception, and found no significant difference in unsuccessful pregnancies, namely, spontaneous abortions, ectopic pregnancies, anembryonic pregnancies, or fetal deaths. They concluded that routine alteration of treatment regimens was not recommended for men taking thiopurines when attempting to conceive. According to a review by Akbari et al[56] concerning the effects of thiopurines on birth outcomes, thiopurine exposure in men with IBD at the time of conception was not associated with congenital abnormalities[28].

In summary, thiopurines do not appear to deteriorate semen quality. Some studies have suggested that paternal thiopurine treatment is associated with an increased risk of pregnancy complications, but in most past studies, paternal thiopurine exposure was not related to congenital malformations.
abnormalities. Regarding the use of thiopurines in male IBD patients who wish to conceive, Sands et al.[28] proposed that health care providers should inform them that there is a possibility of an increased risk of congenital defects and pregnancy complications although fertility does not seem to be affected.

**Methotrexate**

Methotrexate (MTX) is positioned as a second-line immunosuppressive agent used in patients resistant or intolerant to AZA or 6-MP. Polyglutamated metabolites of MTX act through the inhibition of dihydrofolate reductase, and the inhibition of cytokine and eicosanoid synthesis are thought to play a role[40].

MTX is known to have teratogenic effects in women, and it is classified by the American Foods and Drug Administration under Pregnancy Category X, which means that it is contraindicated during pregnancy[41]. However, data are scarce on the effect of MTX on male fertility. Studies of animals exposed to MTX showed altered spermatogenesis, cytotoxicity, and degeneration of spermatocytes, Sertoli cells, and Leydig cells.[15,26,57,58] In 1980, Sussman et al.[29] reported severe oligozoospermia after MTX administration but a return to normal sperm concentrations after discontinuation of MTX. The antifolate mechanism of MTX, which results in decreased DNA synthesis rates and subsequent inhibition of cellular proliferation, likely causes reversible oligozoospermia[28]. El-Beheiry et al.[60] investigated the effects of MTX on fertility potential in 26 male psoriatic patients. They showed no abnormalities in semen analysis, testicular histology, or spermatogenic function observed using radioactive phosphorus, although a longer follow-up was required to rule out the possible teratogenic effects of the drug.

There have been no reports of MTX-induced adverse pregnancy outcomes in men exposed to the drug. Recently, Weber-Schoendorfer et al.[61] performed a prospective observational cohort study involving 113 pregnancies where the father was treated with low-dose MTX around the time of conception. As compared with 412 pregnancies without MTX exposure, no increase was observed in the rate of major birth defects or the complications although fertility does not seem to be affected. MTX was recommended at least 3-4 mo before a planned conception for men with IBD[9,15,56].

**Ciclosporin (cyclosporine)/tacrolimus**

Ciclosporin (CsA) is a calcineurin inhibitor used for treating severe IBD. It prevents clonal expansion of T cell subsets with a rapid onset of action. Tacrolimus is another calcineurin inhibitor, and is often preferred in transplant recipients[43]. CsA and tacrolimus differ in their chemical structure: Tacrolimus is a macrocyclic lactone, while CsA is a cyclic endecapeptide. However, they act in a similar manner as calcineurin inhibitors.

In a review, Sands et al.[23] introduced one study using male mice exposed to CsA, and remarked on the presence of abnormal sperm, oligozoospermia, decreased motility, decreased testicular weight, and decreased testosterone concentrations. A study in rats found that CsA had a deleterious effect on spermiogenesis by directly impairing spermigenic cell development and by impeding Sertoli cell function[65]. In humans, small studies have not found an association between CsA use and male fertility[16,66-68]. There have been no reports of adverse pregnancy outcomes in partners of men receiving CsA.

**Monoclonal antibodies against tumor necrosis factor-alpha**

Three biological agents are used for the treatment of IBD, namely, infliximab (IFX), adalimumab, and certolizumab. All agents are monoclonal antibodies against tumor necrosis factor-alpha (anti-TNF). IFX is a chimeric anti-TNF antibody, consisting of 75% human IgG and 25% murine component. Adalimumab and certolizumab are humanized anti-TNF antibodies. These agents are indicated in CD resistant to standard immunosuppression therapy. IFX is also indicated in UC and fistulating CD[45].

Few studies have examined the effects of anti-TNF on male fertility. IFX is the most studied of the three agents[28]. One animal study using analogous anti-TNF agents revealed no adverse effect on male fertility[74,69]. In a study of 10 men (8 with IBD, 2 with indeterminate colitis), Mahadevan et al.[90] showed a significant increase in semen volume one week after IFX infusion and a trend toward decreased sperm motility. In contrast, in a study of 26 men with spondyloarthritis, Villiger et al.[71] showed no statistically significant difference in sperm quality between healthy controls and patients treated with anti-TNF. They recommended the continuation of anti-TNF treatment when fatherhood was planned. Further, in a prospective study of 10 men with spondylarthritides and 20 healthy male controls, Ramonda et al.[72] found a statistically significant decrease in sperm aneuploidies and normal hormone levels after a 12-mo anti-TNF regimen and concluded that anti-TNF agents appeared to be safe for testicular function and male fertility.

Exposure to anti-TNF agents in men prior to a planned conception does not seem to cause embryo toxicity. One study that investigated medical records of men with ankylosing spondylitis reported that 4 patients had fathered 6 healthy children during IFX treatment[73]. A systematic review by Puchner et al.[79] did not found any documentation of miscarriages or physical abnormalities associated with anti-TNF treatment and paternity. Instead, an improvement in sperm motility and vitality during anti-TNF treatment was shown in that review. The
OTHER FACTORS CAUSING MALE INFERTILITY

Disease activity

Active disease seems to affect male reproductive and sexual function\(^{[15,16]}\). The presence of pro-inflammatory cytokines, including TNF, in the male urogenital tract could lead to cytokine-mediated antifertility effects. Furthermore, inflammation is associated with elevated levels of reactive oxygen species and oxidative stress, both of which have a negative effect on male fertility\(^{[75]}\). Regarding sexual function, Timmer et al\(^{[76]}\) showed that men with IBD in remission or with mild disease activity had similar rates of erectile dysfunction as compared with controls, whereas men with severe IBD activity had higher rates. Thus, control of IBD activity is recommended for men planning to conceive.

Nutrition

Poor nutritional status in men with IBD might cause infertility. El-Tawil suggested a possible relation between decreased testicular function and zinc deficiency, which has been found in up to 70% of patients with CD\(^{[77]}\). To date, no other studies have specifically addressed the contribution of nutritional status to male infertility in IBD, but Feagins et al\(^{[15]}\) proposed that optimizing nutritional status is important for men with IBD who are attempting to father children.

Alcohol use

There are several studies that implicate a negative effect of alcohol consumption on the course of IBD\(^{[78]}\). Swanson et al\(^{[79]}\) showed that alcohol resulted in exacerbation of gastrointestinal symptoms in patients with non-active UC and CD. Jowett et al\(^{[80]}\) indicated that alcohol consumption increased the risk of disease exacerbation in patients with UC. Thus, alcohol use could activate the disease in the patients with IBD. Moreover, past studies implicated alcohol use in decreasing sperm quality and fertility in men\(^{[15,61-83]}\). Alcohol is considered as one of factors that might be contributing to male infertility in men with IBD.

Tobacco use

Smoking is the most researched environmental factor associated with IBD. It has been observed that smoking has a varying impact on CD and UC, contributing to an increased risk for individuals with CD and a protective role in individuals with UC\(^{[1]}\). The mechanism of these paradoxical effects of smoking on CD and UC is not well understood. It is hypothesized that nicotine and oxidative stress play some role\(^{[1,84]}\).

Even if smoking protects against UC, smoking itself impairs fertilization capacity\(^{[65]}\). Tobacco combustion produces many chemical compounds with potential deleterious effects on male germ cells\(^{[85]}\). The toxins originating from cigarette smoke can decrease sperm mitochondrial activity and damage the chromatin structure in human sperm\(^{[83]}\). From a recent meta-analysis of 20 studies with 5865 participants, smoking was found to be a significant risk factor for decreased semen parameters in men\(^{[86]}\). Therefore, smoking cessation is expected to have a positive influence on semen quality and consequently male fertility.

Psychological factor

Past studies showed lower birth rates to men after IBD diagnosis than before diagnosis compared with controls\(^{[8,48]}\). These results meant that IBD men might consider voluntary childlessness apart from physiological factors that could reduce fertility\(^{[87]}\). This voluntary childlessness appears to result from concerns about adverse reproductive outcomes that may not be justified, or patients’ fear of transmitting the disease\(^{[7,88]}\). In a questionnaire survey, Mountifield et al\(^{[78]}\) concluded that patients require accurate counseling addressing fertility and pregnancy outcomes in IBD to assist in their decision-making.

TREATMENT OF INFERTILITY IN MEN WITH IBD

Active inflammation, lifestyle factors (alcohol use, tobacco use), medications, poor nutritional status, and rectal incision seem to affect fertility in male IBD patients\(^{[15]}\). First of all, it is important to control IBD activity. If the patient shows poor nutritional status, optimizing their nutritional status is recommended. Tobacco cessation is strongly recommended when the patient is a smoker. If possible, discontinuation of medications associated with male infertility is recommended for prospective fathers. Table 3 shows the recommendations for each drug. In patients taking sulfasalazine, switching to a different 5-ASA is advised at least 4 mo prior to attempting to conceive\(^{[26]}\). In patients with stable IBD who are receiving mesalazine, discontinuation of the drug might restore fertility\(^{[43]}\). To avoid any potential adverse events, corticosteroids should be used for short periods to control active disease\(^{[28]}\). Although discontinuation of MTX is recommended 3-4 mo before attempting to conceive in most of the past reviews, there is insufficient evidence for males to support this recommendation. The risks of MTX discontinuation might outweigh the unsubstantiated hypothetical benefits. Discontinuation should be considered only in the case of erectile dysfunction. At present, there is insufficient evidence to recommend discontinuation of thiopurines, CsA, and anti-TNF agents such as IFX. Sperm banking should be offered to patients who plan to undergo proctocolectomy, because postoperative anejaculation, despite its low incidence, is a potential irreversible complication.
CONCLUSION

This review aimed to provide further insights into relationship between IBD and male fertility, a topic that has received relatively little attention in the literature. Rectal incision can potentially lead to sexual dysfunction after surgery, and sexual dysfunction may cause male infertility. Of the medications used for IBD, sulfasalazine causes reversible oligoasthenoteratozoospermia. No other medications seem to significantly affect fertility in men although small studies suggested some adverse effects.

In the case of erectile dysfunction, discontinuation of MTX should be considered because MTX appears to be associated with erectile dysfunction. There are limited data about the effects of other drugs on male fertility and pregnancy outcomes; however, patients should be appropriately informed of the possible effects of paternal drug exposure. Considering that IBD predominantly affects young adults of reproductive age, gastroenterologists treating IBD patients should pay more attention to fertility-related issues. Sperm banking is an option for fertility preservation before surgery or initiation of a potentially gonadotoxic medication.

REFERENCES

1. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol 2013; 5: 237-247 [PMID: 23922506 DOI: 10.2147/CLEP.S33961]
2. Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Oresland T, Hultén L. Sexuality in patients with inflammatory bowel disease. Int J Fertil Steril 2007; 1993; 4: 9 [PMID: 19223803 DOI: 10.1038/wigg.2008.90]
3. Rossato M, Forresta C. Antisperm antibodies in inflammatory bowel disease. Arch Intern Med 2004; 164: 2283 [PMID: 15534172]
4. Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic illness and treatment with sulfasalazine on fertility amongst men and women with inflammatory bowel disease in Leicester, UK. Int J Colorectal Dis 1997; 12: 220-224 [PMID: 9272451]
5. Narendranathan M, Sandler RS, Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. J Clin Gastroenterol 1989; 11: 403-406 [PMID: 2760429]
6. Moody GA, Mayberry JF. Perceived sexual dysfunction amongst patients with inflammatory bowel disease. Digestion 1993; 54: 256-260 [PMID: 8248389]
7. Heetun ZS, Brynes C, Neary P, O’Morain C. Review article: Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 2007; 26: 513-533 [PMID: 17661756]
8. Tavernier N, Fumery M, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 847-853 [PMID: 24004045 DOI: 10.1111/apt.12478]
9. Wexner SD, Rosen L, Lowry A, Roberts PL, Burnstein M, Hicks T, Kermer B, Oliver GC, Robertson HD, Robertson WG, Ross TM, Senatoro PJ, Simmang C, Smith C, Vennava AM, Wong WD. Practice parameters for the treatment of mucosal ulcerative colitis—supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1997; 40: 1277-1285 [PMID: 9369100]
10. Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 2002; 184: 45-51 [PMID: 12135718]
11. Gardiner KR, Dasari BV. Operative management of small bowel Crohn’s disease. Surg Clin North Am 2007; 87: 587-610 [PMID: 17560414]
12. Klag T, Goetz M, Stange EF, Wehkamp J. Medical Therapy of Perianal Crohn’s Disease. Visceralmedizin 2015; 31: 265-272 [PMID: 26557835 DOI: 10.1159/000436691]
13. Seifarth C, Kreis ME, Gröne J. Indications and Specific Surgical Techniques in Crohn’s Disease. Visceralmedizin 2015; 31: 273-279 [PMID: 26557836 DOI: 10.1159/000438955]
14. Hwang JM, Varma MG. Surgery for inflammatory bowel disease. World J Gastroenterol 2008; 14: 2678-2690 [PMID: 18461653]
15. Feggin LA, Kane SV. Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol 2009; 104: 768-773 [PMID: 19085421 DOI: 10.1111/j.1572-0241.2008.00751.x]
16. Palomba S, Sereni G, Fallo A, Beltrami M, Lombardini S, Boni MC, Fornaciari G, Sassatelli R, La Sala GB. Inflammatory bowel diseases and human reproduction: a comprehensive evidence-based review. World J Gastroenterol 2014; 20: 7123-7136 [PMID: 24966584 DOI: 10.3748/wjg.v20.i23.7123]
17. Slors FJ, van Zuijlen PP, van Dijk GJ. Sexual and bladder dysfunction after total mesorectal excision for benign diseases. Scand J Gastroenterol Suppl 2000; (232): 48-51 [PMID: 11232492]
18. Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJ. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig Surg 2005; 22: 69-79 [PMID: 15838175]
19. Berndtsson I, Oresland T, Hultén L. Sexuality in patients with ulcerative colitis before and after restorative proctocolectomy: a prospective study. Scand J Gastroenterol 2004; 39: 374-379 [PMID: 15152470]
20. Hueting WE, Gooszen HG, van Laarhoven CJ. Sexual function and continence after ileo pouch anal anastomosis: a comparison between a meta-analysis and a questionnaire survey. Int J Colorectal Dis 2004; 19: 215-218 [PMID: 14564464]
21. Michelassi F, Stella M, Block GE. Prospective assessment of functional results after ileal pouch-anal restorative proctocolectomy. Arch Surg 1993; 128: 899-949; discussion 894-895 [PMID: 8343061]
22. Damgaard B, Wettergren A, Kirkegaard P. Social and sexual function following ileal pouch-anal anastomosis. Dis Colon Rectum 1995; 38: 286-289 [PMID: 7882794]
23. Lindsey I, George BD, Kettlewell MG, Mortensen NJ. Impotence after mesorectal and close rectal dissection for inflammatory bowel disease. Dis Colon Rectum 2001; 44: 831-835 [PMID: 11391143]
24. Lindsey I, George B, Kettlewell M, Mortensen N. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis Colon Rectum 2002; 45: 727-732 [PMID: 12072621]
25. Hultén L. Proctocolectomy and ileostomy to pouch surgery for ulcerative colitis. World J Surg 1998; 22: 335-341 [PMID: 9523513]
26. Sands K, Jansen R, Zaslau S, Greenwald D. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 2015; 41: 821-834 [PMID: 25725723 DOI: 10.1111/apt.13142]
27. Levi AJ, Fisher AM, Hughes L, Hendry WE. Male infertility due to sulfasalazine. Lancet 1979; 2: 276-278 [PMID: 88609]
28. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-842 [PMID: 6136396]
29. O’Morain C, Smethurst P, Doré CJ, Levi AJ. Reversible male infertility due to sulfasalazine: studies in man and rat. Gut 1984; 25: 1078-1084 [PMID: 6148293]
30. Birnie GG, McLeod T, Watkinson G. Incidence of sulfasalazine-induced male infertility. Gut 1991; 22: 452-455 [PMID: 614898]
male infertility: reversibility and possible mechanism. Gut 1981; 22: 445-451 [PMID: 6114897]
34 Fukushina T, Hamada Y, Komiyama M, Matsumo Y, Morii C, Horii I. Early changes in sperm motility, acrosome reaction, and gene expression of reproductive organs in rats treated with sulfasalazine. *Reprod Toxicol* 2007; 23: 153-157 [PMID: 17166698 DOI: 10.1016/j.reprotox.2006.10.003]
35 Alonso V, Linares V, Bellés M, Albina ML, Sirvent JT, Domingo JL, Sánchez DJ. Sulfasalazine induced oxidative stress: a possible mechanism of male infertility. *Reprod Toxicol* 2009; 27: 35-40 [PMID: 19028562 DOI: 10.1016/j.reprotox.2008.10.007]
36 Linares V, Alonso V, Domingo JL. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. *Expert Opin Drug Saf* 2011; 10: 253-263 [PMID: 21219240 DOI: 10.1517/14740338.2011.529989]
37 Wu FC, Atken RJ, Ferguson A. Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation. *Fertil Steril* 1989; 52: 842-845 [PMID: 2572460]
38 Cosentino MJ, Chey WY, Takahashi H, Cockett AT. The effects of sulfasalazine on human male fertility potential and seminal prostanoids. *J Urol* 1984; 132: 682-686 [PMID: 6147421]
39 Riley SA, Lecarpentier J, Mani V, Goodman MJ, Mandel BK, Turnberg LA. Sulfasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. *Gut* 1987; 28: 1008-1012 [PMID: 2899648 DOI: 10.1136/gut.28.10.1008]
40 Chatzinof M, Guarino JM, Corson SL, Batzer FR, Friedman LS. Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas. *Dig Dis Sci* 1988; 33: 108-110 [PMID: 2892654 DOI: 10.1007/BF01536639]
41 Zeilissen PM, van Hattum J, Poen H, Scholten P, Younge L, Lees C, Ho GT, Satsangi JL, Sanchez DJ. Sulfasalazine induced oxidative stress: a possible mechanism of male infertility. *Am J Gastroenterol* 2010; 105: 2003-2008 [PMID: 20700117 DOI: 10.1088/ag.2010.138]
42 Akbari M, Shah S, Velayos FS, Mahadevan U, Chieftz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2013; 19: 15-22 [PMID: 22454610 DOI: 10.1002/ibd.22248]
43 Saxena AK, Dhungel S, Bhattacharya S, Jha CB, Srivastava AK. Effect of chronic low dose of methotrexate on cellular proliferation during spermatogenesis in rats. *Arch Androl* 2004; 50: 33-35 [PMID: 14660169]
44 Shrestha S, Dhungel S, Saxena AK, Bhattacharya S, Maskey D. Effect of methotrexate (MTX) administration on methotrexate: an experimental on animal model. *J Urol* 1998; 9: 230-233 [PMID: 18298010]
45 Sussman A, Leonardi JM. Psoriasis, methotrexate, and oligospermia. *Arch Dermatol* 1980; 116: 215-217 [PMID: 7356357]
46 El-Beheyri AI, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. *Arch Androl* 1979; 17: 177-179 [PMID: 518200]
47 Weber-Schoendorfer C, Hoefzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. *Rheumatology (Oxford)* 2014; 53: 75-763 [PMID: 24369441 DOI: 10.1093/rd/aou390]
48 Blackburn WD, Alarcon GS. Impotence in three rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum* 1989; 32: 1341-1342 [PMID: 2803334 DOI: 10.1002/art.1780321029]
49 Riba N, Moreno F, Costa J, Olive A. [Appearance of impotence in relation to the use of methotrexate]. *Med Clin (Barc)* 1996; 106: 558 [PMID: 8656751]
50 Thomas E, Koumouvi K, Blomman F. Impotence in a patient with rheumatoid arthritis treated with methotrexate. *J Rheumatol* 2000; 27: 1821-1822 [PMID: 10914881]
51 Masuda H, Fujihira S, Ueno H, Kagawa M, Katsuoka Y, Morii H. Ultrastructural study on cytotoxic effects of cyclosporine A in spermogenesis in rats. *Med Electron Microsc* 2003; 36: 183-191 [PMID: 14505063 DOI: 10.1007/s00795-003-0213-4]
52 Bouloux PM, Wess JA, Parslow JM, Hendry WF, Besser GM. Effect of cyclosporin A in male autoimmune infertility. *Fertil Steril* 1986; 46: 81-85 [PMID: 3720982]
53 Sakamoto Y, Matsumoto T, Kamazawa J. Cell-mediated autoimmune response to testis induced by bilateral testicular injury can be suppressed by cyclosporin A. *J Urol* 1998; 159: 1735-1740 [PMID: 9554403 DOI: 10.1097/00005392-199805000-00103]
54 Haberman J, Karwa G, Greenstein SM, Soberman R, Glicklich D, Tellis V, Melman A. Male fertility in cyclosporine-treated renal transplant patients. *J Urol* 1991; 145: 294-296 [PMID: 1988720]
55 Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized...
